Expression of trisomic proteins in Down syndrome model systems

Gene

Volumn 512, Issue 2, 2013, Pages 219-225

  Spellman, Claire ^a   Ahmed, Md Mahiuddin ^a   Dubach, Daphne ^a   Gardiner, Katheleen J ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

Cortex; Gene dosage; Protein expression; Tc1; Trisomy 21; Ts65Dn

Indexed keywords

PROTEIN ADARB1; PROTEIN ANTIBODY; PROTEIN C21ORF59; PROTEIN CBS; PROTEIN CCT8; PROTEIN CHAF1B; PROTEIN DONSON; PROTEIN FTCD; PROTEIN IFNGR2; PROTEIN LCASL; PROTEIN MX1; PROTEIN NDUFV3; PROTEIN PFKL; PROTEIN PRMT2; PROTEIN PWP2; PROTEIN RRP1; PROTEIN SH3BGR; PROTEIN SIM2; PROTEIN TMPRSS3; PROTEIN ZNF294; PROTEIN ZNF295; UNCLASSIFIED DRUG;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; CHROMOSOME 21; CONTROLLED STUDY; DOWN SYNDROME; GENE EXPRESSION; HUMAN; HUMAN CELL; LYMPHOBLASTOID CELL LINE; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; TRISOMY; WESTERN BLOTTING;

ADULT; ANIMALS; CELL LINE; CEREBRAL CORTEX; CHROMOSOMES, HUMAN, PAIR 21; DOWN SYNDROME; FEMALE; GENE DOSAGE; GENE EXPRESSION REGULATION; HUMANS; MALE; MICE; NERVE TISSUE PROTEINS; RNA, MESSENGER;

MUS;

EID: 84870317158     PISSN: 03781119     EISSN: 18790038     Source Type: Journal    
DOI: 10.1016/j.gene.2012.10.051     Document Type: Article

References (28)

1. Ahmed M.M., Gardiner K.J. Preserving protein profiles in tissue samples: differing outcomes with and without heat stabilization. J. Neurosci. Methods 2011, 196:99-106.
2. Ahmed Md.M., Sturgeon X., Ellison M., Davisson M.T., Gardiner K.J. Loss of correlations among proteins in brains of the Ts65Dn mouse model of Down syndrome. J. Proteome Res. 2012, 11:1251-1263.
3. Aït Yahya-Graison E., et al. Classification of human chromosome 21 gene-expression variations in Down syndrome: impact on disease phenotypes. Am. J. Hum. Genet. 2007, 81:475-491.
4. CDC, Centers for Disease Control and Prevention Improved National Prevalence Estimates for 18 Major Birth Defects. MMWR Morb. Mortal. Wkly Rep. 2006, 54:6-12.
5. Cheon M.S., et al. Protein levels of genes encoded on chromosome 21 in fetal Down syndrome brain: challenging the gene dosage effect hypothesis (Part III). Amino Acids 2003, 24:127-134.
6. Cheon M.S., Dierssen M., Kim S.H., Lubec G. Protein expression of BACE1, BACE2 and APP in Down syndrome brains. Amino Acids 2008, 35:339-343.
7. Choi J.H., et al. Age-dependent dysregulation of brain amyloid precursor protein in the Ts65Dn Down syndrome mouse model. J. Neurochem. 2009, 110:1818-1827.
8. Henderson A., Lynch S.A., Wilkinson S., Hunter M. Adults with Down's syndrome: the prevalence of complications and health care in the community. Br. J. Gen. Pract. 2007, 57:50-55.
9. Irving C., Basu A., Richmond S., Burn J., Wren C. Twenty-year trends in prevalence and survival of Down syndrome. Eur. J. Hum. Genet. 2008, 16:1336-1340.
10. Jones A.R., Overly C.C., Sunkin S.M. The Allen Brain Atlas: 5 years and beyond. Nat. Rev. Neurosci. 2009, 10:821-828.
11. Kuhn S., et al. Auditory function in the Tc1 mouse model of Down syndrome suggests a limited region of human chromosome 21 involved in otitis media. PLoS One 2012, 7:e31433.
12. Lott I.T., Dierssen M. Cognitive deficits and associated neurological complications in individuals with Down's syndrome. Lancet Neurol. 2010, 9:623-633.
13. Lyle R., Gehrig C., Neergaard-Henrichsen C., Deutsch S., Antonarakis S.E. Gene expression from the aneuploid chromosome in a trisomy mouse model of Down syndrome. Genome Res. 2004, 14:1268-1274.
14. Maier T., Güell M., Serrano L. Correlation of mRNA and protein in complex biological samples. FEBS Lett. 2009, 583:3966-3973.
15. Mangan M.E., Williams J.M., Lathe S.M., Karolchik D., Lathe W.C. UCSC genome browser: deep support for molecular biomedical research. Biotechnol. Annu. Rev. 2008, 14:63-108.
16. O'Doherty A., et al. An aneuploid mouse strain carrying human chromosome 21 with Down syndrome phenotypes. Science 2005, 309:2033-2037.
17. Prandini P., et al. Natural gene-expression variation in Down syndrome modulates the outcome of gene-dosage imbalance. Am. J. Hum. Genet. 2007, 81:252-263.
18. Reeves R.H., et al. A mouse model for Down syndrome exhibits learning and behaviour deficits. Nat. Genet. 1995, 11:177-184.
19. Roubertoux P.L., Carlier M. Mouse models of cognitive disabilities in trisomy 21 (Down syndrome). Am. J. Med. Genet. C Semin. Med. Genet. 2010, 154C:400-416.
20. Schwanhäusser B., et al. Global quantification of mammalian gene expression control. Nature 2011, 473:337-342.
21. Sheppard O., et al. Altered regulation of tau phosphorylation in a mouse model of Down syndrome aging. Neurobiol. Aging 2012, 33:828.e31-828.e44.
22. Siddiqui A., Lacroix T., Stasko M., Costa A.C., Gardiner K. Molecular response of the Ts65Dn and Ts1Cje mouse models of Down syndrome to the NMDA receptor antagonist, MK-801. Genes Brain Behav. 2008, 7:810-819.
23. Slavov D., Gardiner K. Phylogenetic comparisons of the ADAR2 RNA editases: gene structures, editing and alternative splicing. Gene 2002, 299:83-94.
24. Sturgeon X., Gardiner K. Comparative transcript catalogs of human chromosome 21 and orthologous chimpanzee and mouse genomic regions. Mamm. Genome 2011, 22:61-71.
25. Sturgeon X., Le L., Ahmed Md.M., Gardiner K.J. Pathways to cognitive deficits in Down syndrome. Prog. Brain Res. 2012, 197:73-100.
26. Sultan M., et al. Gene expression variation in Down's syndrome mice allows prioritization of candidate genes. Genome Biol. 2007, 8:R91.
27. Vilardell M., et al. Meta-analysis of heterogeneous Down syndrome data reveals consistent genome-wide dosage effects related to neurological processes. BMC Genomics 2011, 12:229-338.
28. Wiseman F.K., Alford K.A., Tybulewicz V.L., Fisher E.M. Down syndrome-recent progress and future prospects. Hum. Mol. Genet. 2009, 18:R75-R83.